Banner Pharmacaps, Inc., a drug delivery and specialty pharmaceutical company, engages in the research, development, and manufacture of oral dosage forms for the pharmaceutical health care industry. It develops drug delivery systems and patented technologies, including Soflet Gelcaps, a technology that enrobes tablets with a gelatin or non-animal film; LiquiSoftT Chewable Liquid-Filled Softgels, which is a chewable gel dosage form suitable for pediatric populations; Chewel, a soft chewable gelatin dosage form for pediatric populations; EnteriCare, which are enteric softgels; Versatrol, which is a controlled release softgel technology; and EcoCaps, which are non-animal softgels. It serves pharmaceutical and biotechnology, and consumer healthcare markets. The company was founded in 1994 and is headquartered in High Point, North Carolina. It has drug manufacturing facilities in High Point, North Carolina; Tilburg, the Netherlands; Olds, Canada; and Mexico City, Mexico. It has locations in Mexico, Europe, the Asia/Pacific, the United States, and Canada. Banner Pharmacaps, Inc. operates as a subsidiary of VION N.V.

BioDelivery Sciences International, Inc. company was founded in 1997 and is based in Raleigh, North Carolina. BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB.BioDelivery Sciences Company's products/formulations also include BEMA Buprenorphine, which is under preparation for phase 2 for moderate to severe and acute pain. Its lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. The company also has a Bioral formulation, which is in initial in vitro studies for the intranasal administration of Amphotericin B to treat chronic rhinosinusitis. BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease.

Zogenix is intent on alleviating that nasty migraine of yours. The biopharmaceutical company is focused on developing and commercializing central nervous system (CNS) and therapeutic pain medications. The company received FDA approval for its Sumavel DosePro (sumatriptan) candidate in 2009. The drug, previously known as Intraject, utilizes the company's needle-free drug delivery technology and administers sumatriptan for the relief of acute migraines and cluster headaches. Its other late-stage candidate, ZX002, is an oral controlled release formulation of hydrocodone, used for the treatment of chronic pain. Biotechnology veteran Cam Garner founded Zogenix in 2006.

Hollis-Eden Pharmaceuticals, Inc. company was founded in 1992 and is headquartered in San Diego, California. Hollis-Eden Pharmaceuticals Inc., a development stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases and disorders, in which the body is unable to mount immune or metabolic response due to disease or the process of aging. The company focuses on developing a series of adrenal steroid hormones and hormone analogs that are derived from its Hormonal Signaling Technology Platform. It develops two clinical drug development candidates, TRIOLEX (HE3286), which is in initial clinical trials for the treatment of type 2 diabetes, ulcerative colitis, and rheumatoid arthritis; and APOPTONE (HE3235) that is in a clinical trial for late-stage prostate cancer. The company is also exploring APOPTONE for other cancers, such as breast cancer. In addition, Hollis-Eden Pharmaceuticals has a research program that is generating clinical leads for evaluation in preclinical models of various diseases, including metabolic and autoimmune conditions, as well as inflammatory diseases of the lung, bone metabolism, and regenerative medicine.

Stratagene has a strategy for using genes to reach success. The company makes reagents, kits, and other products for gene and protein analysis, gene transfer, protein purification, DNA replication, and other molecular biology applications. It also makes medical diagnostics including allergy testing kits, autoimmune tests that diagnose such disorders as rheumatoid arthritis, and the KOVA urinalysis system. Stratagene sells its products in more than 60 countries; in key markets, the firm uses its own sales force and relies on distributors for other markets. The company is a division of scientific instrument-maker Agilent.

Bio-Botanica was founded in 1972 by CEO Frank D'Amelio. Bio-Botanica Inc. company develops and manufactures a variety of botanical extracts used by customers throughout the US and internationally, in the nutraceutical, food and beverage, and cosmetics industries. Bio-Botanica's more than 300 extracts come in solid, semi-solid, powdered, and liquid forms and are used as both active ingredients and preservatives in products ranging from teas to soaps and homeopathic remedies. The company also produces its own line of consumer products, including extracts and blended nutritional supplements, which are sold through retailers under the Nature's Answer brand.

Ranbaxy Pharmaceuticals Inc. company, the US arm of Indian generic pharmaceuticals giant Ranbaxy Laboratories Limited, makes and markets about 50 generic and over-the-counter (OTC) drugs. It accounts for about a quarter of its parent's annual revenues. RPI's generic offerings, produced by manufacturing subsidiary Ohm Laboratories, include anti-infectives and treatments for cardiovascular, gastrointestinal, and central nervous system disorders. Its OTC products include analgesics, antihistamines, and decongestants. Sister subsidiary Ranbaxy Laboratories, Inc. (RLI) develops branded pharmaceuticals.

CEO Samuel Bogoch founded Oncolab shortly after he discovered the technology for detecting anti-malignin antibodies in the 1960s. Oncolab, Inc. company makes the AMAS test, an early warning blood screening test for cancer. The test detects abnormal levels of anti-malignin antibody which may indicate the presence of tumors. It is the first antibody that can be directly related to the survival of cancer patients and can be easily detected even before malignin reaches a detectable level. The test is shipped for free and is administered by doctors, then sent to Oncolab to process the results (for a fee); there are also a handful of lab locations that administer the test.

ActivX Biosciences figures that the more you know about protein kinases, the easier it will be to inhibit them. That's the basis of its main product: a platform to profile protein kinases -- enzymes that regulate cell's signaling pathways. Its KiNativ platform has been launched for use by pharmaceutical and biotechnology companies as they develop the kinase inhibitors expected to make drug breakthroughs. The company also has its own pipeline of drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.

MEDA PHARMACEUTICALS INC. is the U.S. subsidiary of Meda AB. Meda Pharmaceuticals specializes in respiratory, allergy, central nervous system, and cough-cold products. MEDA AB is an international specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company’s strategy. Meda is represented with own organizations in 26 countries and with more than 1,500 employees within marketing and sales. Meda’s products are sold in approximately 120 countries world-wide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.